EUCTR2015-002590-38-FI进行中（未招募）1 期
A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer - ARASENS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 1,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Subjects must meet the following criteria at the time of Screening:
- •1. Written informed consent.
- •2. Males =18 years of age.
- •3. Histologically or cytologically confirmed adenocarcinoma of prostate.
- •4. Metastatic disease documented either by a positive bone scan, or for soft tissue or visceral metastases, either by contrast-enhanced abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging (MRI) scan assessed by Investigator and confirmed by central radiology review. Metastatic disease is defined as either malignant lesions in bone scan or measurable lymph nodes above the aortic bifurcation or soft tissue/visceral lesions according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Lymph nodes are measurable if the short axis diameter is =15 mm, soft tissue/visceral lesions are measurable if the long axis diameter is =10 mm.
- •Subjects with regional lymph node metastases only (N1, below the aortic bifurcation) will not be eligible for the study. Only subjects with non-regional lymph node metastases (M1a) and/or bone metastases (M1b) and/or other sites of metastases with or without bone disease (M1c) will be eligible.
- •5. Subjects must be candidates for ADT and docetaxel therapy per Investigator’s judgment.
- •6. Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but no longer than 12 weeks before randomization. For subjects receiving LHRH agonists, treatment in combination with a first generation anti-androgen for at least 4 weeks prior to randomization is recommended. First generation anti-androgen has to be stopped prior to randomization.
- •7. An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
- •8. Blood counts at Screening: hemoglobin =9.0 g/dL, absolute neutrophil count =1.5x109/L, platelet count =100x109/L (subject must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory sample obtained at Screening).
- •9. Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) =1.5 x upper limit of normal (ULN), total bilirubin =ULN, creatinine =2.0 x ULN.
- •10. Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with darolutamide /placebo and for 3 months after treatment with darolutamide/placebo and 6 months after treatment with docetaxel.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 650
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 650
排除标准
- •Subjects who meet any of the following criteria at the time of Screening will be excluded:
- •1. Prior treatment with:
- •LHRH agonist/antagonists started more than 12 weeks before randomization
- •Second-generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, darolutamide, other investigational AR inhibitors
- •Cytochrome P 17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as antineoplastic treatment for prostate cancer
- •Chemotherapy or immunotherapy for prostate cancer prior to randomization
- •2. Treatment with radiotherapy (external beam radiation therapy [EBRT], brachytherapy, or radiopharmaceuticals) within 2 weeks before randomization.
- •3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs.
- •4. Contraindication to both CT and MRI contrast agent.
- •5. Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV).
- •6. Uncontrolled hypertension as indicated by a resting systolic BP =160 mmHg or diastolic BP =100 mmHg despite medical management.
- •7. Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed =5 years before randomization and from which the subject has been disease-free.
- •8. A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study drug.
- •9. An active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease with a need of treatment.
- •10. Previous (within 28 days before the start of study drug or 5 half-lives of the investigational treatment of the previous study, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s).
- •11. Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject’s participation in the study or evaluation of the study results.
- •12. Inability to swallow oral medications.
- •13. Close affiliation with the investigational site (e.g., a close relative of the Investigator, dependent person [e.g., employee or student of the investigational site]).
- •14. Previous assignment to treatment in this study.
研究者
相似试验
招募中
1 期
A study to determine the safety, tolerability and pharmacokinetics of ZYAN1 following oral administration in healthy volunteers.AnemiaACTRN12614001240639Cadila Healthcare Limited100
已完成
3 期
A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy.NL-OMON35789Hoffmann-La Roche32
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).Estudio de fase III aleatorizado, doble ciego, controlado con placebo de SGN-35 (brentuximab vedotin) y mejor tratamiento asistencial (BSC) frente a placebo y BSC en el tratamiento de pacientes con alto riesgo de linfoma de Hodgkin (HL) residual tras trasplante autólogo de células madre (ASCT)Patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).Pacientes con alto riesgo de linfoma de Hodgkin (HL) residual tras trasplante autólogo de células madre (ASCT)MedDRA version: 12.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaEUCTR2009-016947-20-ESSeattle Genetics, Inc.329
Unknown
1 期
A clinical study toevaluate the safety, tolerability and pharmacokinetics of oral ZYGK1 in healthy volunteersCTRI/2011/12/002249Zydus Research Centre96
进行中（未招募）
不适用
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy.EUCTR2010-024468-16-CZF. Hoffmann-La Roche Ltd610